MBRX
Moleculin Biotech, Inc.
Key Financials
Operating Income
$-25103000
↑ 5.8%
Net Income
$-33560000
↓ 54.2%
Revenue
$0
NaN%
Total Liabilities
$7.1M
↓ 35.0%
Total Assets
$22.1M
↑ 30.7%
Cash & Equivalents
$8.9M
↑ 107.5%
Operating Cash Flow
$-22735000.00
↑ 4.7%
Shareholders' Equity
$15.0M
↑ 151.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 9/29/2026 | View on SEC |
| 8-K | 9/28/2026 | View on SEC |
| 8-K | 9/25/2026 | View on SEC |
| 8-K | 9/23/2026 | View on SEC |
| 8-K | 9/18/2026 | View on SEC |
| 8-K | 9/14/2026 | View on SEC |
| 8-K | 8/31/2026 | View on SEC |
| SCHEDULE 13D | 8/25/2026 | View on SEC |
| SCHEDULE 13D | 8/25/2026 | View on SEC |
| DEFA14A | 8/24/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | MBRX |
| Company Name | Moleculin Biotech, Inc. |
| CIK | 1659617 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 713-300-5160 |